Leuprolide

Summary

Leuprolide (CHEMBL1201199) is an approved protein antineoplastic agent (ATC L02AE02) targeting GNRHR; indicated across 21 conditions including neoplasm and metastatic prostate carcinoma; with CIViC clinical evidence for 1 variant-indication association (e.g. AR OVEREXPRESSION in salivary gland cancer).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L02AE02
• Targets: 1 (GNRHR)
• Indications: 21 conditions
• Clinical trials: 235
• Precision-oncology evidence (CIViC): 1 variant–indication association
• Chemistry: 1209.4 Da · C59H84N16O12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201199
Name	Leuprolide
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	657181
ChEBI	CHEBI:6427
ATC	L02AE02
Molecular formula	C59H84N16O12
Molecular weight	1209.4
InChIKey	GFIJNRVAKGFPGQ-LIJARHBVSA-N

SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6

IUPAC name: (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

ChEBI definition: An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.

Pharmacological roles (ChEBI): antineoplastic agent, gonadotropin releasing hormone agonist, anti-estrogen.

Also known as: (-)-leuprolide, ABBOTT-43818 FREE BASE, CKD-841, Leuporelin, Leuprolide, Leuprorelin, Leuprorelin slow release, Leuprorelina, Leuproreline, NSC-377526, TAP-144 FREE BASE, leuprorelin

Parent form; salt/anhydrous children: CHEMBL1200775, CHEMBL4802223

Patent coverage: 22,632 distinct patent families (95,230 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 94,438 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GNRHR	GnRH1 receptor	Full agonist	9.1	0.1%	P30968

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
GNRHR	9.54	IC50	0.29	nM	CHEMBL_ACT_16447825
GNRHR	9.52	IC50	0.3	nM	CHEMBL_ACT_1114893
GNRHR	9.52	IC50	0.3	nM	CHEMBL_ACT_1745035
P30969	9.3	IC50	0.5	nM	CHEMBL_ACT_1114895
P30969	9.3	IC50	0.5	nM	CHEMBL_ACT_1744997
P30969	9.1	IC50	0.8	nM	CHEMBL_ACT_1114894
GNRHR	9.1	IC50	0.8	nM	CHEMBL_ACT_1744999

Target pathways

Aggregated over 1 target gene(s): GNRHR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Hormone ligand-binding receptors	1	GNRHR
G alpha (q) signalling events	1	GNRHR

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	1
gonadotropin secretion	1
cellular response to hormone stimulus	1
signal transduction	1
cellular response to gonadotropin-releasing hormone	1

Indications & clinical

Indications

7 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
metastatic prostate carcinoma	3	MONDO:0004956	EFO:0000196
prostate adenocarcinoma	3	MONDO:0005082	EFO:0000673
prostate carcinoma	3	MONDO:0005159	EFO:0001663
benign muscle neoplasm	3	MONDO:0003061	MONDO:0003061
breast neoplasm	3	MONDO:0021100	MONDO:0007254
breast carcinoma	3	MONDO:0004989	EFO:0000305

9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
infertility disorder	3	MONDO:0005047	EFO:0000545
endometriosis	3	MONDO:0005133	EFO:0001065
uterine corpus leiomyoma	3	MONDO:0007886	EFO:0000731
leiomyoma	3	MONDO:0001572	MONDO:0001572
melanoma	2	MONDO:0005105	EFO:0000756
hypogonadism	2	MONDO:0002146	MONDO:0002146
salivary gland cancer	2	MONDO:0004669	MONDO:0000521
obesity disorder	1	MONDO:0011122	EFO:0001073
HIV infectious disease	1	MONDO:0005109	EFO:0000764

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 235.

Phase distribution

Phase	Trials
PHASE2	96
PHASE3	59
Not specified	26
PHASE4	24
PHASE1	13
PHASE1/PHASE2	10
EARLY_PHASE1	4
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06627530	PHASE4	ACTIVE_NOT_RECRUITING	COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer
NCT00220194	PHASE4	COMPLETED	A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
NCT00349258	PHASE4	COMPLETED	The Use of GnRH Agonist Trigger in the Prevention of OHSS
NCT00455689	PHASE4	COMPLETED	Understanding Experimentally Induced Hot Flushes
NCT00505817	PHASE4	COMPLETED	GnRH Agonist and Antagonists in an Oocyte Donation Program
NCT00621179	PHASE4	COMPLETED	Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
NCT00805935	PHASE4	COMPLETED	Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
NCT01116401	PHASE4	COMPLETED	Impact of Hot Flashes on Sleep and Mood Disturbance
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01921166	PHASE4	COMPLETED	Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study
NCT02069808	PHASE4	COMPLETED	Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation
NCT02158845	PHASE4	COMPLETED	Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis
NCT02357563	PHASE4	UNKNOWN	Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation
NCT02361879	PHASE4	UNKNOWN	Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma
NCT02361905	PHASE4	UNKNOWN	Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas
NCT02427958	PHASE4	COMPLETED	A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants
NCT02969590	PHASE4	COMPLETED	Regulation of Cervical Mucus Secretion
NCT02974270	PHASE4	UNKNOWN	Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate
NCT03035032	PHASE4	COMPLETED	A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
NCT03421639	PHASE4	UNKNOWN	Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis
NCT04094467	PHASE4	UNKNOWN	Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
NCT04248621	PHASE4	UNKNOWN	Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
NCT05304169	PHASE4	COMPLETED	Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.
NCT05341115	PHASE4	COMPLETED	A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
NCT01674140	PHASE3	ACTIVE_NOT_RECRUITING	S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT02344472	PHASE3	ACTIVE_NOT_RECRUITING	Detect V / CHEVENDO (Chemo vs. Endo)
NCT02685397	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Management of Castration-Resistant Prostate Cancer with Oligometastases
NCT03678025	PHASE3	RECRUITING	Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT04302454	PHASE3	ACTIVE_NOT_RECRUITING	Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
NCT04423211	PHASE3	RECRUITING	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04455750	PHASE3	ACTIVE_NOT_RECRUITING	A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
NCT04484818	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
NCT04513717	PHASE3	ACTIVE_NOT_RECRUITING	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT05050084	PHASE3	ACTIVE_NOT_RECRUITING	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05493709	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
NCT05781217	PHASE3	RECRUITING	Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
NCT05827081	PHASE3	RECRUITING	Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT06449027	PHASE3	ACTIVE_NOT_RECRUITING	Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
NCT06650579	PHASE3	RECRUITING	REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
NCT00002580	PHASE3	COMPLETED	Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
NCT00002582	PHASE3	COMPLETED	Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
NCT00002633	PHASE3	COMPLETED	Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
NCT00002881	PHASE3	COMPLETED	Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
NCT00003645	PHASE3	TERMINATED	Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
NCT00003653	PHASE3	COMPLETED	Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
NCT00004635	PHASE3	COMPLETED	Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
NCT00076531	PHASE3	COMPLETED	Clinical Trial for Prostate Cancer
NCT00128531	PHASE3	COMPLETED	Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
NCT00220350	PHASE2/PHASE3	UNKNOWN	Lupron Sex Offender Therapy
NCT00283062	PHASE3	COMPLETED	Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
NCT00295750	PHASE3	COMPLETED	The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
NCT00355030	PHASE3	COMPLETED	Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature
NCT00380406	PHASE3	COMPLETED	PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial
NCT00388804	PHASE3	TERMINATED	External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
NCT00514917	PHASE3	TERMINATED	A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
NCT00541047	PHASE3	COMPLETED	RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
NCT00598312	PHASE3	COMPLETED	Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
NCT00601276	PHASE3	TERMINATED	Comparison of Two Pharmacological Treatments of Pedophilia
NCT00626431	PHASE3	COMPLETED	A Study of Leuprolide to Treat Prostate Cancer
NCT00630799	PHASE3	TERMINATED	Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
NCT00635817	PHASE3	COMPLETED	A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
NCT00651326	PHASE3	TERMINATED	Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
NCT00667446	PHASE3	COMPLETED	Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
NCT00687739	PHASE3	COMPLETED	Prevention of Obesity in Women Via Estradiol Regulation
NCT00740831	PHASE3	COMPLETED	PGL4001 Versus GnRH-agonist in Uterine Myomas
NCT00928434	PHASE3	COMPLETED	A Study of Degarelix in Patients With Prostate Cancer
NCT00949962	PHASE3	TERMINATED	Post-operative or Early Salvage XRT and ADT for High Risk PCa
NCT01011751	PHASE3	COMPLETED	Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
NCT01712763	PHASE3	COMPLETED	Degarelix in the Treatment of Endometriosis Recurrence
NCT02085252	PHASE3	COMPLETED	A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
NCT02262416	PHASE3	UNKNOWN	GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles
NCT02452931	PHASE3	COMPLETED	Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
NCT02655237	PHASE3	COMPLETED	A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
NCT02663908	PHASE3	TERMINATED	A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
NCT02736435	PHASE3	WITHDRAWN	Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound
NCT02914158	PHASE3	UNKNOWN	Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
NCT02941926	PHASE3	COMPLETED	Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
NCT02980965	PHASE3	COMPLETED	Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
NCT03070886	PHASE2/PHASE3	COMPLETED	Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03085095	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
NCT03544073	PHASE3	WITHDRAWN	GnRH Agonist at Embryo Transfer: IVF Outcomes
NCT03695237	PHASE3	COMPLETED	A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
NCT04914195	PHASE3	COMPLETED	Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
NCT05440383	PHASE3	COMPLETED	A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
NCT05605964	PHASE3	COMPLETED	Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
NCT06025409	PHASE3	UNKNOWN	Evaluate the Efficacy and Safety of DWJ108J
NCT00544830	PHASE2	ACTIVE_NOT_RECRUITING	Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT01786265	PHASE2	ACTIVE_NOT_RECRUITING	Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
NCT02960022	PHASE2	RECRUITING	A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT03361735	PHASE2	ACTIVE_NOT_RECRUITING	Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT03902951	PHASE2	ACTIVE_NOT_RECRUITING	Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
NCT03951831	PHASE2	ACTIVE_NOT_RECRUITING	REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
NCT04194554	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
NCT04734730	PHASE2	RECRUITING	Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT05320406	PHASE2	ACTIVE_NOT_RECRUITING	RElugolix VErsus LeUprolide Cardiac Trial
NCT05478083	PHASE2	RECRUITING	A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
NCT05669664	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
NCT05765500	PHASE2	RECRUITING	RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT05896293	PHASE2	RECRUITING	Kisspeptin Administration Subcutaneously to Patients With IHH
NCT05924256	PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
AR OVEREXPRESSION	Salivary Gland Cancer	Sensitivity/Response	Bicalutamide + Leuprolide	CIViC B	EID6953

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

13 molecules share ≥1 primary target. Top 13 by shared-target count:

Molecule	Source	Status	Shared targets
CETRORELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
DEGARELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ELAGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
GANIRELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
RELUGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ABARELIX	ChEMBL	Phase 4 (approved)	GNRHR
GONADORELIN	ChEMBL	Phase 4 (approved)	GNRHR
LINZAGOLIX	ChEMBL	Phase 4 (approved)	GNRHR
ACYLINE	ChEMBL	Phase 2	GNRHR
SUFUGOLIX	ChEMBL	Phase 2	GNRHR
Belzutifan	PubChem	Approved	GNRHR
Deslorelin	PubChem	Approved	GNRHR
Triptorelin	PubChem	Approved	GNRHR